Recognition—a first in the industry—advances continuous quality improvement mission
WALTHAM, Mass.--(BUSINESS WIRE)-- Fresenius Medical Care (NYSE: FMS), the world’s leading company devoted to renal therapy, said today that the U.S. Agency for Healthcare Research and Quality officially recognized the company’s Patient Safety Organization (PSO.) The certification by the U.S. Secretary of the Department of Health and Human Services, the first for a dialysis organization, furthers Fresenius Medical Care’s mission of continuously improving patient safety and health care quality. The purpose of a PSO is to establish a framework by which doctors and other health care providers may voluntarily report information to PSOs, on a privileged and confidential basis, to collect and analyze patient safety events. Regulations outline how the PSO may utilize data and act as a resource for health care providers to understand and minimize the risks and hazards in delivering patient care.
A PSO's workforce must have expertise in analyzing patient safety events, such as the identification, analysis, prevention, and reduction or elimination of the risks and hazards associated with the delivery of patient care.
“Each of our more than 1,800 kidney dialysis clinics in the U.S. has a Quality Improvement Committee that investigates the root causes of all patient adverse events, with the objective of continuous improvement in patient safety and quality of care,” said Michael Lazarus, M.D., director of Fresenius Medical Care Patient Safety Organization. “Our companywide Patient Safety Organization performs a more global root cause analysis of aggregate data. We do this to maximize safe conditions in our facilities and to provide the safest dialysis treatments possible. When we find unsafe situations or processes that lead to errors, it is important to change our approach and to educate the staff as well as the patients about any unsafe conditions so that together we can eliminate them.”
About Fresenius Medical Care
Fresenius Medical Care (NYSE: FMS) is the world’s leading company devoted to patient-oriented renal therapy. Through more than 2,700 clinics in North America, Europe, Latin America, Asia-Pacific and Africa, we provide kidney dialysis treatments to approximately 215,000 patients worldwide. We are also the world's leading maker of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Chronic kidney failure is a condition that affects about 1.9 million individuals worldwide. For more information about the company’s more than 1,800 U.S. dialysis facilities, visit www.ultracare-dialysis.com (in English and Spanish). For more information about Fresenius Medical Care, visit www.fmc-ag.com or www.fmcna.com.
Fresenius Medical Care
Jane A. Kramer
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Hospitals Medical Devices Pharmaceutical Other Health FDA Medical Supplies General Health